Yeast; Media Therefor Patents (Class 435/254.2)
-
Publication number: 20140322162Abstract: Methods and compositions for treating an iron disorder in a patient are presented, including methods for orally administering a recombinant yeast that produces H-ferritin-iron complex or the H-ferritin-iron complex extracted from the yeast. Data indicate that administration of the recombinant yeast more effectively increases hemoglobin, hematocrit and transferrin saturation than an iron-equivalent amount of FeSO4. A recombinant yeast expressing human H-ferritin or H-ferritin-iron complex is also presented.Type: ApplicationFiled: July 1, 2014Publication date: October 30, 2014Applicant: Chyna, LLCInventors: James R. Connor, Stephanie Patton, Raymond Stevens
-
Publication number: 20140322129Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.Type: ApplicationFiled: March 13, 2014Publication date: October 30, 2014Applicant: Genentech, Inc.Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
-
Publication number: 20140322224Abstract: The invention relates to monoclonal antibodies (mAbs) that bind to serotransferrin (TF), hybridoma lines that secrete these antibodies or fragments thereof, and the use of these antibodies to detect TF antigens. Methods and uses for detecting prostate cancer, as well as methods and uses for distinguishing early and late stage prostate cancer are encompassed.Type: ApplicationFiled: November 9, 2012Publication date: October 30, 2014Applicant: ALPER BIOTECH LLCInventor: Ozge Alper
-
Publication number: 20140322218Abstract: The present invention provides to a antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention relates to a nucleic acid sequence encoding the antibody construct, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention relates a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: ApplicationFiled: January 27, 2014Publication date: October 30, 2014Applicant: AMGEN RESEARCH (MUNICH) GMBHInventors: Shouhua Xiao, Zheng Pan, Dineli Wickramasinghe, Shawn Jeffries, Chadwick T. King, Brian Mingtung Chan, Peter Kufer, Ralf Lutterbüse, Tobias Raum, Patrick Hoffmann, Doris Rau, Roman Kischel, Bryan Lemon, Holger Wesche
-
Publication number: 20140322770Abstract: The present invention relates to isolated polypeptides having peroxygenaseactivity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 28, 2012Publication date: October 30, 2014Inventors: Sara Landvik, Lars Henrik Oestergaard, Lisbeth Kalum
-
Publication number: 20140322776Abstract: The invention relates to recombinant yeast host cells that overexpress proteins to improve glucose utilization, pentose sugar utilization and/or production of a fermentation product in a fermentation reaction.Type: ApplicationFiled: August 31, 2012Publication date: October 30, 2014Applicant: CODEXIS, INC.Inventors: Oscar Alvizo, Galit Meshulam-Simon, Amy Lum, Dayal Saran
-
Publication number: 20140322764Abstract: What is aimed at is provision of an inexpensive and efficient saccharification method for lignocellulose using a thermostable xylanase and provision of a mutant xylanase that has a substitute amino acid residue, and that exhibits stable activity even under severe conditions in which enzymes easily inactivate, and that provides an initial rate of reaction not significantly reduced as compared to a wild-type xylanase corresponding to the mutant xylanase. Provided is a method of producing a saccharified product of lignocellulose, including contacting a lignocellulosic raw material with a thermostable xylanase, and a mutant xylanase that provides an initial rate of reaction that is at least 70% of that provided by a wild-type xylanase corresponding thereto, that has a xylanase activity after heat treatment at 50° C. for 24 hours that is at least 50% of its xylanase activity before the heat treatment, and that has a substitute amino acid residue.Type: ApplicationFiled: November 22, 2012Publication date: October 30, 2014Inventors: Hisaaki Yanai, Hiroki Tamai, Masami Osabe, Fumikazu Yokoyama, Kaoru Okakura, Atsushi Inoue
-
Publication number: 20140325711Abstract: The present invention relates to isolated polypeptides having lysozyme activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 23, 2012Publication date: October 30, 2014Inventors: Kirk Matthew Schnorr, Jens Erik Nielsen, Mikkel Klausen
-
Patent number: 8871488Abstract: The present invention is related to recombinant host cells comprising: (i) at least one deletion, mutation, and/or substitution in an endogenous gene encoding a polypeptide that converts pyruvate to acetaldehyde, acetyl-phosphate or acetyl-CoA; and (ii) a heterologous polynucleotide encoding a polypeptide having phosphoketolase activity. The present invention is also related to recombinant host cells further comprising (iii) a heterologous polynucleotide encoding a polypeptide having phosphotransacetylase activity.Type: GrantFiled: June 15, 2011Date of Patent: October 28, 2014Assignee: Butamax Advanced Biofuels LLCInventors: Michael Dauner, Lori Ann Maggio-Hall, Jean-Francois Tomb
-
Publication number: 20140314770Abstract: The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.Type: ApplicationFiled: February 5, 2014Publication date: October 23, 2014Applicant: Celera CorporationInventors: Elizabeth JOSELOFF, Steve RUBEN, Tao HE
-
Publication number: 20140315279Abstract: The present invention provides systems for producing engineered oleaginous yeast or fungi that express quinone derived compounds.Type: ApplicationFiled: December 12, 2013Publication date: October 23, 2014Applicant: DSM IP ASSETS b.v.Inventors: Richard B. Bailey, Kevin T. Madden, Joshua Trueheart
-
Publication number: 20140314797Abstract: Lower eukaryotic host cells have been engineered to produce glycoprotein having at least one terminal ?-galactosyl epitope. The glycoproteins are useful for the production of highly antigenic glycoprotein compositions with advantages for the production of vaccines.Type: ApplicationFiled: July 2, 2014Publication date: October 23, 2014Inventors: Natarajan Sethuraman, Robert C. Davidson, Terrance A. Stadheim, Stefan Wildt
-
Publication number: 20140314832Abstract: The present invention relates to pharmaceutical and medical technologies, and more particularly to novel nanobodies against pulmonary surfactant protein A (SP-A) and their preparation methods. The nanobodies of the present invention comprises an amino acid sequence having certain formula. The present invention also relates to nucleic acid sequences encoding the nanobodies, their preparation method and their applications. Immunohistochemistry and in vivo imaging show that the nanobodies of the present inventions have high lung-targeting specificity.Type: ApplicationFiled: August 2, 2013Publication date: October 23, 2014Applicant: Shanghai Pulmonary Hospital, Tongji University School of MedicineInventors: Huiping Li, Shanmei Wang
-
Publication number: 20140314831Abstract: Disclosed is a recombinant polypeptide for facilitating membrane fusion. The recombinant polypeptide having a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein and having a functional myristoylation motif, a transmembrane domain from a FAST protein and a sequence with at least 80% sequence identity with the endodomain of p15 FAST protein. A targeting ligand can be added to the recombinant polypeptide for selective fusion. The recombinant polypeptide can be included in the membrane of a liposome, or the like, to facilitate the delivery of bioactive compounds, such as siRNA, or the recombinant polypeptide can be mixed with a lipid carrier and added to cultured cells to induce cell-cell fusion and heterokaryon formation.Type: ApplicationFiled: September 29, 2011Publication date: October 23, 2014Applicant: Innovascreen Inc.Inventors: Roy Duncan, John Lewis, Roberto Justo De Antueno, Rae-Lynn Nesbitt, Eileen Kathryn Clancy
-
Publication number: 20140314858Abstract: The present invention provides bivalent oral vaccines against infectious pancreatic necrosis virus (IPNV) and infectious salmon anemia virus (ISAV). Yeast cells comprise an expression vector comprising (i) a polynucleotide sequence encoding a VP2 capsid protein of IPNV and (ii) a polynucleotide sequence encoding one or more antigenic epitopes of hemaglutinin of ISAV. The yeast cells express sub-viral particles (SVP) comprising a VP2 capsid protein of IPNV and one or more antigenic epitopes of hemaglutinin of ISAV. The yeast cells and SVP may be administered in an effective amount to increase the amount of antibodies against IPNV and ISAV in the fish, preferably Salmonidae. The yeast cells and SVP may be in the form of fish food for administering to the fish orally.Type: ApplicationFiled: September 7, 2012Publication date: October 23, 2014Applicant: Advanced BioNutrition CorporationInventor: Arun K. Dhar
-
Publication number: 20140317786Abstract: The present invention relates to isolated polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 16, 2012Publication date: October 23, 2014Inventor: Marc Morant
-
Publication number: 20140315246Abstract: The present invention provides a novel endo-?-N-acetylglucosaminidase (Endo-Om) using a transformant produced by cloning an endo-?-N-acetylglucosaminidase (Endo-Om) gene originated from a methylotrophic yeast Ogataea minuta IFO10746 strain. The Endo-Om according to the present invention has a specific activity 13-fold higher than that of known Endo-M and a Vmax value 55-fold higher than that of the known Endo-M, and is useful for the analysis of the structures of sugar chains, including complex type sugar chains, in glycoproteins and the modification of the sugar chains.Type: ApplicationFiled: October 3, 2012Publication date: October 23, 2014Applicant: National Institute of Advanced Industrial Science and TechnologyInventors: Yasunori Chiba, Satoshi Murakami, Hisashi Narimatsu
-
Publication number: 20140315310Abstract: The invention provides, inter alia, recombinase-based systems that provide for integrated logic and memory in living cells.Type: ApplicationFiled: December 13, 2013Publication date: October 23, 2014Applicant: Massachusetts Institute of TechnologyInventors: Timothy Kuan-Ta Lu, Piro Siuti
-
Publication number: 20140315274Abstract: The invention relates to: a method for producing a protease in yeast, comprising providing a yeast host cell comprising at least one polynucleotide expression construct encoding a first polypeptide secreted by the host cell in translational fusion with a second polypeptide, wherein the second polypeptide is a protease having a mature amino acid sequence similar to that of SEQ ID NO:2; the corresponding yeast host cell and the expression construct.Type: ApplicationFiled: November 5, 2012Publication date: October 23, 2014Applicant: NOVOZYMES A/SInventor: Tomoka Matsui
-
Publication number: 20140315299Abstract: The invention provides a fusion protein comprising, from N-terminus to C-terminus: a) a first portion of a Family B G-protein coupled receptor (GPCR) that comprises transmembrane helix (TM)-1, TM2 and TM3 of the GPCR; b) a stable protein domain; and c) a second portion of the GPCR comprising TM4, TM5, TM6 and TM7 of the GPCR. The invention also provides a method of crystallising a GPCR comprising providing the fusion protein of the invention and crystallising it to obtain crystals.Type: ApplicationFiled: August 9, 2012Publication date: October 23, 2014Applicant: Heptares Therapeutics LimitedInventors: Seyed Ali Jazayeri-Dezfuly, Fiona Hamilton Marshall
-
Publication number: 20140314727Abstract: The present invention relates to methods of synthesizing long-chain polyunsaturated fatty acids, especially eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid, in recombinant cells such as yeast or plant cells. Also provided are recombinant cells or plants which produce long-chain polyunsaturated fatty acids. Furthermore, the present invention relates to a group of new enzymes which possess desatorase or elongase activity that can be used in methods of synthesizing long-chain polyunsaturated fatty acids.Type: ApplicationFiled: July 3, 2014Publication date: October 23, 2014Applicant: Commonwealth Scientific and Industrial Research OrganisationInventors: Surinder Pal Singh, Stanley Suresh Robert, Peter David Nichols, Susan Irene Ellis Blackburn, Xue-Rong Zhou, James Robertson Petrie, Allan Graham Green
-
Publication number: 20140315804Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.Type: ApplicationFiled: March 13, 2014Publication date: October 23, 2014Applicant: GENZYME CORPORATIONInventors: Peter PECHAN, Jeffery ARDINGER, Hillard RUBIN, Samuel WADSWORTH, Abraham SCARIA
-
Patent number: 8865429Abstract: Transgenic oleaginous yeast having increased oil content comprising increased Yap1 transcription factor activity, wherein the increased oil content is compared to the oil content of a non-transgenic oleaginous yeast, are described herein. The increased Yap1 transcription factor activity results from overexpressing a Yap1 transcription factor, by increasing the interaction between the transcription factor and a protein that is capable of activating the transcription factor, or by a combination thereof. Methods of using these yeast strains are also described.Type: GrantFiled: December 29, 2011Date of Patent: October 21, 2014Assignee: E I du Pont de Nemours and CompanyInventors: Seung-Pyo Hong, Zhixiong Xue, Quinn Qun Zhu
-
Publication number: 20140308247Abstract: This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing one or more proteins under the control of a gene expression modulation, system in the presence of activating ligand and uses for therapeutic purposes in animals. The vector may be provided to treat or prevent disease.Type: ApplicationFiled: March 2, 2012Publication date: October 16, 2014Applicant: Intrexon CorporationInventors: Jeremiah F. Roeth, Brandon Cuthbertson, Charles C. Reed, Sunil Chada, William E. Fogler, Fayas Khazi
-
Publication number: 20140308717Abstract: The present invention relates to a method comprising the steps a) providing a secondary alcohol, b) oxidizing the secondary alcohol by contacting it with an NAD(P)+-dependent alcohol dehydrogenase and c) contacting the oxidation product of step a) with a transaminase, wherein the NAD(P)+-dependent alcohol dehydrogenase and/or the transaminase is a recombinant or isolated enzyme, to a whole cell catalyst for carrying out the method, and to the use of such a whole cell catalyst for oxidizing a secondary alcohol.Type: ApplicationFiled: July 27, 2012Publication date: October 16, 2014Applicant: Evonik Degussa GmbHInventors: Thomas Haas, Markus Poetter, Jan Christoph Pfeffer, Wolfgang Kroutil, Arne Skerra, Alexandra Lerchner, Katharina Christin Tauber, Johann H. Sattler, Steffen Schaffer
-
Publication number: 20140308724Abstract: The present invention is directed to a yeast strain, or strains, secreting a full suite, or any subset of that full suite, of enzymes to hydrolyze corn starch, corn fiber, lignocellulose, (including enzymes that hydrolyze linkages in cellulose, hemicellulose, and between lignin and carbohydrates) and to utilize pentose sugars (xylose and arabinose). The invention is also directed to the set of proteins that are well expressed in yeast for each category of enzymatic activity. The resulting strain, or strains can be used to hydrolyze starch and cellulose simultaneously. The resulting strain, or strains can be also metabolically engineered to produce less glycerol and uptake acetate. The resulting strain, or strains can also be used to produce ethanol from granular starch without liquefaction.Type: ApplicationFiled: February 12, 2014Publication date: October 16, 2014Applicants: Stellenbosch University, Mascoma CorporationInventors: Elena BREVNOVA, John E. McBride, Erin Wiswall, Kevin S. Wenger, Nicky Caiazza, Heidi Hau, Aaron Argyros, Frank Agbogbo, Charles F. Rice, Trisha Barrett, John S. Bardsley, Abigail Foster, Anne K. Warner, Mark Mellon, Ryan Skinner, Indraneel Shikhare, Riaan Den Haan, Chhayal V. Gandhi, Alan Belcher, Vineet B. Rajgarhia, Allan C. Froehlich, Kristen M. Deleault, Emily Stonehouse, Shital A. Tripathi, Jennifer Gosselin, Yin-Ying Chiu, Haowen Xu
-
Publication number: 20140308266Abstract: The present invention is concerned with modified neurotoxins. Specifically, it relates to a modified biologically active neurotoxin polypeptide comprising at least one poly-Glycine domain. Also contemplated is a polynucleotide encoding the modified neurotoxin polypeptide having a poly-Glycine domain fused to the N-terminus, to the C-terminus or to both of the heavy and/or light chain of the mature neurotoxin polypeptide, vector comprising it and a host cell comprising such a polynucleotide or a vector. Moreover, envisaged are the aforementioned compounds for use as a medicament for treating various diseases.Type: ApplicationFiled: November 8, 2012Publication date: October 16, 2014Inventor: Karl-Heinz Eisele
-
Publication number: 20140308286Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: March 19, 2014Publication date: October 16, 2014Applicant: AbbVie Inc.Inventors: Tariq Ghayur, Jochen G. Salfeld, Michael J. McPherson, Maria C. Harris, Junjian Liu, Peter C. Isakson, Jijie Gu
-
Publication number: 20140308735Abstract: Yeast cells with reduced activity of certain enzymes involved in branched chain amino acid biosynthesis in yeast mitochondria are described. Target enzymes include threonine deaminase, isopropylmalate synthase, and optionally branched chain amino acid transaminase.Type: ApplicationFiled: June 11, 2014Publication date: October 16, 2014Applicant: BUTAMAX ADVANCED BIOFUELS LLCInventor: Larry Cameron ANTHONY
-
Publication number: 20140308699Abstract: A Yeast Artificial Chromosome (YAC) directing the expression of one or more activities of the humanized glycosylation pathway is provided. The said YAC comprises one or more expression cassettes for fusion proteins of heterologous glycosylation pathway and an ER/Golgi retention sequence. The invention also relates to new yeast cells which contain the said YAC. Finally, the invention also provides a method for producing recombinant target glycoproteins.Type: ApplicationFiled: August 1, 2011Publication date: October 16, 2014Applicant: GLYCODEInventors: Christophe Javaud, Vincent Carre
-
Publication number: 20140308258Abstract: The present invention provides enhanced microorganisms useful for inhibiting and/or preventing the proliferation of pathogenic microorganisms such as methicillin-resistant Staphylococcus aureus and methicillin-resistant Staphylococcus epidermidis.Type: ApplicationFiled: April 11, 2014Publication date: October 16, 2014Inventor: Charles Joseph Matthews
-
Publication number: 20140309400Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor (poly-)peptides, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of dry eye syndrome.Type: ApplicationFiled: November 30, 2012Publication date: October 16, 2014Inventors: Jean-Marc Combette, Catherine Deloche
-
Publication number: 20140308271Abstract: The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.Type: ApplicationFiled: January 2, 2014Publication date: October 16, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: ANTOINE ATTINGER, JONATHAN ALBERT BACK, STANISLAS BLEIN, RAMI LISSILAA, DARKO SKEGRO
-
Publication number: 20140308291Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides methods of inducing an immune response against a panton-valentine leukocidin (PVL)-expressing S. aureus, methods of preventing or treating S. aureus infections, and composition for preventing or treating S. aureus infections.Type: ApplicationFiled: November 30, 2012Publication date: October 16, 2014Inventors: Mohammad Javad Aman, Rajan Prasad Adhikari, Hatice Karauzum, Jawad Sarwar, Sergey Shulenin, Sathya Venkataramani, Kelly Lyn Warfield, Tam Luong Nguyen
-
Patent number: 8859240Abstract: The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) antigens from WNV (the secreted envelope glycoprotein (E), the heterodimer glycoproteins (pre-M-E) and the NSI protein) and from Dengue virus (the secreted envelope glycoprotein (e), the heterodimer glycoproteins (pre-m-e) and the nsl protein) and their use in vaccinal, therapeutic and diagnostic applications.Type: GrantFiled: June 2, 2009Date of Patent: October 14, 2014Assignees: Institut Pasteur, Centre National de la Recherche ScientifiqueInventors: Frédéric Tangy, Philippe Despres, Chantal Combredet, Marie Pascale Frenkiel
-
Patent number: 8859248Abstract: This invention provides a method for improving the xylose-metabolizing ability of a yeast strain having xylose-metabolizing ability. The method comprises steps of: soaking the yeast strain having xylose-metabolizing ability in an acetic-acid-containing solution; and then, culturing the yeast strain in a xylose-containing medium to perform ethanol fermentation.Type: GrantFiled: November 11, 2010Date of Patent: October 14, 2014Assignee: Toyota Jidosha Kabushiki KaishaInventors: Toru Onishi, Emiko Tominaga, Noriko Yasutani
-
Expression cassette for lactase dehydrogenase, transformed yeast and method of producing lactic acid
Patent number: 8859260Abstract: A gene expressing cassette codes lactate dehydrogenase that is needed for prevention of deterioration in lactic acid yield and lactic acid production rate in continuous culture with simultaneous filtration of a yeast strain having a lactic acid-producing ability, which achieves high optical purity, high lactic acid yield and high lactic acid production rate simultaneously, a yeast strain having the cassette and a method of producing lactic acid by culturing the yeast strain. The lactate dehydrogenase-expressing cassette is a lactate dehydrogenase-expressing cassette, comprising a gene coding lactate dehydrogenase connected to a site downstream of a promoter, the promoter being a promoter of a gene showing a gene expression amount larger by 5 times or more than the average relative expression amount of all genes after 50 hours from start of culture in continuous culture with simultaneous filtration of a yeast strain having a lactic acid-producing ability.Type: GrantFiled: December 5, 2008Date of Patent: October 14, 2014Assignee: Toray Industries, Inc.Inventors: Kenji Sawai, Hideki Sawai -
Patent number: 8859261Abstract: Provided herein are compositions and methods for the heterologous production of acetyl-CoA-derived isoprenoids in a host cell. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding an acetaldehyde dehydrogenase, acetylating (ADA, E.C. 1.2.1.10) and an MEV pathway comprising an NADH-using HMG-CoA reductase. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding an ADA and an MEV pathway comprising an acetoacetyl-CoA synthase. In some embodiments, the genetically modified host cell further comprises one or more heterologous nucleotide sequences encoding a phosphoketolase and a phosphotransacetylase. In some embodiments, the genetically modified host cell further comprises a functional disruption of the native PDH-bypass. The compositions and methods described herein provide an energy-efficient yet redox balanced route for the heterologous production of acetyl-CoA-derived isoprenoids.Type: GrantFiled: October 24, 2013Date of Patent: October 14, 2014Assignee: Amyris, Inc.Inventors: Timothy Stevens Gardner, Kristy Michelle Hawkins, Adam Leon Meadows, Annie Ening Tsong, Yoseph Tsegaye
-
Patent number: 8859855Abstract: Disclosed are chimeric polyunsaturated fatty acid (PUFA) olyketide synthase (PKS) proteins and chimeric PUFA PKS systems, including chimeric PUFA PKS proteins and systems derived from Schizochytrium and Thraustochytrium. Disclosed are nucleic acids and proteins encoding such chimeric PUFA PKS proteins and systems, genetically modified organisms comprising such chimeric PUFA PKS proteins and systems, and methods of making and using such chimeric PUFA PKS proteins and systems.Type: GrantFiled: October 2, 2012Date of Patent: October 14, 2014Assignee: DSM IP Assets B.V.Inventors: Craig A. Weaver, Ross Zirkle, Daniel H. Doherty, James G. Metz
-
Publication number: 20140302076Abstract: The present invention provides compositions relating to viral capsomeres which comprise foreign immunogenic sequences for use in pharmaceutical compositions and methods of producing such compositions, and related isolated or purified protein and nucleic acid molecules, vectors, host cells, compositions, and methods of use to augment an immune response, immunise an animal and prophylactically or therapeutically treat a disease, disorder or condition. The viral capsomere may be derived from a polyomavirus and comprise an immunogen of interest at the N-terminus and further at the C-terminus and/or at one or more exposed loops of the capsomere.Type: ApplicationFiled: August 13, 2012Publication date: October 9, 2014Applicant: THE UNIVERSITY OF QUEENSLANDInventors: Anton Peter Jacob Middelberg, Linda Hwee-Lin Lua
-
Publication number: 20140303036Abstract: The present invention relates to a method for the preparation of a library of host cells, a plurality of which comprise an assembled polynucleotide at a target locus, which method comprises: (a) providing a plurality of polynucleotides comprising two or more polynucleotide subgroups, wherein: (i) a plurality of polynucleotides in each polynucleotide subgroup comprises sequence encoding a peptide or polypeptide and/or a regulatory sequence; (ii) a plurality of peptides or polypeptides encoded by, or a plurality of regulatory sequences comprised within, each polynucleotide subgroup share an activity and/or function; (iii) at least one polynucleotide subgroup comprises at least two non-identical polynucleotide species; (iv) a plurality of polynucleotides of each polynucleotide subgroup comprises sequence enabling homologous recombination with a plurality of polynucleotides from one or more other polynucleotide subgroups; and (v) a plurality of polynucleotides in two polynucleotide subgroups comprise a nucleotideType: ApplicationFiled: November 23, 2012Publication date: October 9, 2014Inventors: Johannes Andries Roubos, Bernard Meijrink, Richard Kerkman, Ben Den Dulk
-
Publication number: 20140304859Abstract: Provided are isolated polypeptides having endoglucanase activity and polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: December 14, 2012Publication date: October 9, 2014Applicant: Novozymes Inc.Inventors: Ye Liu, Yu Zhang, Junxin Duan, Lan Tang
-
Publication number: 20140302574Abstract: Methods and materials related to producing 3-HP as well as other organic compounds are disclosed. Specifically, isolated nucleic acids, polypeptides, host cells, and methods and materials for producing 3-HP and other organic compounds are disclosed.Type: ApplicationFiled: June 17, 2014Publication date: October 9, 2014Applicant: Cargill, IncorporatedInventors: Ravi R. Gokarn, Olga V. Selifonova, Holly Jean Jessen, Steven John Gort, Thorsten Selmer, Wolfgang Buckel
-
Publication number: 20140302041Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.Type: ApplicationFiled: June 22, 2012Publication date: October 9, 2014Applicants: ORIBASE PHARMA, Institut Regional du Cancer de Montpellier-Val d' Aurelle, INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE MONTPELLIER 1Inventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
-
Publication number: 20140302542Abstract: A flavin-binding glucose dehydrogenase having high substrate specificity for D-glucose and decreased reactivity to D-xylose and/or maltose. More specifically, a flavin-binding glucose dehydrogenase having one or more amino acid substitutions at a position corresponding to position 78, position 79, position 81, position 121, position 122, position 123, position 569 and position 612 of Mucor-derived flavin-binding glucose dehydrogenase. The flavin-binding glucose dehydrogenase enables D-glucose to be measured accurately without being susceptible to the effects of the presence of D-xylose and/or maltose, even under conditions of mounting a large amount of an enzyme such as in glucose sensors.Type: ApplicationFiled: November 1, 2012Publication date: October 9, 2014Applicant: KIKKOMAN CORPORATIONInventors: Yasuko Araki, Atsushi Ichiyanagi, Keiichi Ichikawa, Kozo Hirokawa
-
Publication number: 20140302035Abstract: Provided herein are tandem Fcs and tandem Fc antibodies (“TFcAs”), e.g., tandem Fc bispecific antibodies (“TFcBAs”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a TFc, which TFc comprises a first Fc region and a second Fc region, wherein the first and the second Fc regions are linked through a TFc linker to form a contiguous polypeptide and dimerize to form an Fc dimer. Exemplary TFcBAs bind to the cell surface receptors c-Met and EpCam and inhibit signal transduction through the cell surface receptor(s) for which the binding sites of the TFcBA are specific.Type: ApplicationFiled: March 6, 2014Publication date: October 9, 2014Applicants: ADIMAB, LLC, MERRIMACK PHARMACEUTICALS, INC.Inventors: Brian HARMS, Neeraj KOHLI, Alexey LUGOVSKOY, Melissa GEDDIE, Eric Mark KRAULAND, WIlliam George ROACH, Stephen SU, Adnan ABU-YOUSIF
-
Publication number: 20140302025Abstract: Provided are chimeric VEGF-binding proteins and nucleic acids (e.g., a vector) encoding chimeric VEGF-binding proteins, methods and host cells for producing these proteins and nucleic acids, and pharmaceutical compositions containing these proteins and nucleic acids. Also provided are methods of treating an angiogenic disease or disorder that include administering at least one of the chimeric VEGF-binding proteins or at least one of the nucleic acids (e.g., a vector) encoding a chimeric VEGF-bind ing protein.Type: ApplicationFiled: August 17, 2012Publication date: October 9, 2014Applicants: CHILDREN'S MEDICAL CENTER CORPORATION, THE GENERAL HOSPITAL CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Bob Carter, Jeng-Shin Lee, Szofia S. Bullain, Richard C. Mulligan
-
Publication number: 20140303084Abstract: Provided are pro-coagulant compounds (e.g., pro-coagulant peptides or peptide derivatives) and methods of using and making those compounds. Further provided are conjugates between a pro-coagulant compound of the present disclosure (e.g., pro-coagulant peptide or peptide derivative) and a polypeptide selected from FIX, FVIIa, FVIII, and platelet targeting moieties (e.g., PDG-13), wherein the compound is linked to the polypeptide optionally via a linker. The compounds and conjugates are useful for the treatment of coagulation disorders, such as hemophilia A and hemophilia B. Further provided are methods of using and making the conjugates.Type: ApplicationFiled: June 9, 2012Publication date: October 9, 2014Applicant: Biogen IDEC MA Inc.Inventors: Karina Thorn, Garabet G. Toby, Adam R. Mezo
-
Publication number: 20140302040Abstract: The present invention provides an antibody that recognizes a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 15 in the Sequence Listing and has an anti-arthritic function, or a functional fragment thereof.Type: ApplicationFiled: May 15, 2013Publication date: October 9, 2014Inventors: Satomichi Yoshimura, Tatsuya Kurihara, Kayoko Kawashima, Masato Hoshino, Kumiko Kadoshima, Maki Tsujimoto, Takako Kimura, Jun Hasegawa
-
Publication number: 20140294828Abstract: The invention provides methods for the production of single-chain Alphabody polypeptides having detectable binding affinity for, or detectable in vitro activity on, a viral protein of interest, which comprising the step of producing a single-chain Alphabody library comprising at least 100 different-sequence single-chain Alphabody polypeptides, wherein said Alphabody polypeptides differ from each other in at least one of a defined set of 5 to 20 variegated amino acid residue positions, and wherein said variegated amino acid residue positions are located at specific positions in one or more of the alpha-helices of the Alphabody or the linker fragment connecting two consecutive alpha-helices of the Alphabody polypeptides. The invention further provides Alphabodies obtainable by the methods of the invention and uses thereof.Type: ApplicationFiled: January 6, 2011Publication date: October 2, 2014Applicant: COMPLIX SAInventors: Johan Desmet, Ignace Lasters, Geert Meersseman, Sabrina Deroo